RNAZ
TransCode Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.24
P/S
0.00
EV/EBITDA
-0.20
DCF Value
$9.74
FCF Yield
-176.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-684.9%
ROA
-519.1%
ROIC
-754.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-4.9M | $-5.82 |
| Q2 2025 | $0.00 | $-4.3M | $-5.13 |
| Q1 2025 | $0.00 | $-12.1M | $-70.28 |
| Q4 2024 | $0.00 | $-5.9M | $-16.61 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.50
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.